AdvanTIG-206

Recruiting

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Beigene Study ID info

AdvanTIG-206

ClinicalTrials.gov ID info

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents